Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test - Seite 2

The MyT4(TM) CD4 test supports countries' efforts to decentralize HIV treatment, expanding access to healthcare for remote populations and relieving the burden at centralized facilities. According to WHO, there are 9.7 million people in developing countries on antiretroviral therapy today but another 16 million people are unable to access the treatment they need. Point-of-care diagnostic testing is a critical tool to determine treatment eligibility and link greater numbers of HIV positive people to lifesaving treatment.

"To curb the AIDS epidemic, we must expand access to testing and treatment globally," said Ben Plumley, CEO of Pangaea Global AIDS Foundation. "Rapid, affordable and accessible point-of-care CD4 and viral load diagnostics are critical for enabling us to reach vulnerable groups and better identify who needs to initiate or adjust treatment."

The MyT4(TM) CD4 test is the first of an expanding line of diagnostic tests that originate from Zyomyx's portfolio of proprietary platform technologies capable of moving laboratory tests for cells, proteins and infectious agents to the point-of-care and thereby providing immediate benefits to clinicians, healthcare workers and patients in multiple disease areas.

About Zyomyx, Inc.

Zyomyx, Inc. has developed a proprietary cell capture and analysis platform to enable quick low-cost diagnosis for infectious diseases. The platform is focused on a suite of diagnostics for antibiotic resistance where same day results at the point-of-care have a major impact on treatment outcomes and health care costs. The company's first product, an inexpensive CD4 T-cell point-of-care test, demonstrates the potential of Zyomyx's capture and analysis technology. Zyomyx, which is based in Fremont, California, is privately held. For more information, visit http://www.zyomyx.com.

About UNITAID

Based in Geneva and hosted by the World Health Organization, UNITAID uses innovative financing to increase funding for greater access to treatments and diagnostics for HIV/AIDS, malaria and tuberculosis in low-income countries. Approximately half of UNITAID's resources come from a small levy on airline tickets in several countries, while the rest is provided primarily by multi-year contributions from governments and a foundation. As of the end of 2011, this levy has collected US$ 1.06 billion - 66% of the US$ 1.6 billion raised by UNITAID.

CONTACT: Karen Schlein, 510-456-1749, [e-mail]

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zyomyx via Globenewswire

HUG#1771721